APOL1 and chronic kidney disease: Provision of APOL1 genotype led to increased urine microalbumin screening (between-group difference, 17.3% [95% CI, 9.6%-24.9%]; P < .001) and CKD diagnoses (between-group difference, 5.7% [95% CI, 2.2%-9.3%]; P = .002) at 6 months.<h4>Conclusions and relevance</h4>Provision of APOL1 genotype high-risk results to participants and clinicians was not associated with SBP reduction overall.